FourWorld Capital Management’s Starling Oncology STLN Stock Holding History

FourWorld Capital Management’s Portfolio STLN Stock Details STLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.71M	Hold	499,196	–	–	2.47%	15
2026 Q1	$1.53M	Buy	499,196 +116,496	+30%	+$357K	0.78%	17
2025 Q4	$1.36M	Buy	382,700 +24,700	+7%	+$91.6K	1.1%	14
2025 Q3	$1.25M	Sell	358,000 -33,650	-9%	-$115K	1.97%	13
2025 Q2	$803K	Buy	391,650 +134,650	+52%	+$337K	0.54%	16
2025 Q1	$293K	Hold	257,000	–	–	0.19%	19
2024 Q4	$79.4K	Hold	257,000	–	–	0.04%	19
2024 Q3	$84K	Hold	257,000	–	–	0.05%	24
2024 Q2	$118K	Buy	257,000 +6,641	+3%	+$5.67K	0.07%	24
2024 Q1	$396K	Buy	+250,359	New	+$476K	0.25%	25

Other funds holding STLN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JAIC

Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

FourWorld Capital Management's STLN Position: Q2 2026 in Review

FourWorld Capital Management held its Starling Oncology (STLN) position steady in Q2 2026 at 499,196 shares worth $2.71M. The position accounts for 2.47% of the portfolio, ranked #15.

FourWorld Capital Management first reported a position in STLN in Q1 2024 and has held it in 10 quarters since. 119 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

FourWorld Capital Management held 499,196 shares of Starling Oncology worth $2.71M as of Q2 2026.
FourWorld Capital Management left its Starling Oncology share count unchanged in Q2 2026.
Starling Oncology made up 2.47% of FourWorld Capital Management's portfolio in Q2 2026, its #15 holding.
FourWorld Capital Management first reported a position in Starling Oncology in Q1 2024 and has held it in 10 quarters since.
119 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2026.

Based on FourWorld Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.